These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27716991)

  • 21. Two patients with fluoropyrimidine overdose successfully managed without uridine triacetate.
    Kats CJ; Jochems A; Jeurissen FJ; Ledeboer A; van den Berg RB
    J Oncol Pharm Pract; 2023 Dec; 29(8):2037-2040. PubMed ID: 37499216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In brief: uridine triacetate (Vistogard) for fluorouracil overdose.
    Med Lett Drugs Ther; 2016 Jul; 58(1498):90. PubMed ID: 27348145
    [No Abstract]   [Full Text] [Related]  

  • 23. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
    Johnson MR; Hageboutros A; Wang K; High L; Smith JB; Diasio RB
    Clin Cancer Res; 1999 Aug; 5(8):2006-11. PubMed ID: 10473079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-Fluorouracil Neurotoxicity in a Patient With Normal Dihydropyrimidine Dehydrogenase Activity.
    Natarajan U; Onyechi A; Ohemeng-Dapaah J
    Cureus; 2023 Dec; 15(12):e49898. PubMed ID: 38174188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.
    Morrison GB; Bastian A; Dela Rosa T; Diasio RB; Takimoto CH
    Oncol Nurs Forum; 1997; 24(1):83-8. PubMed ID: 9007910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
    Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
    Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients.
    Katona C; Kralovánszky J; Rosta A; Pandi E; Fónyad G; Tóth K; Jeney A
    Oncology; 1998; 55(5):468-74. PubMed ID: 9732227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
    Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
    J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
    Dong QM; He YJ; Li S; Zhou ZM; Zhang L; Zhou ZW; Xia ZJ; Li YY
    Ai Zheng; 2005 Apr; 24(4):483-7. PubMed ID: 15820075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
    Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].
    Lemaitre F; Goirand F; Launay M; Chatelut E; Boyer JC; Evrard A; Paludetto MN; Guilhaumou R; Ciccolini J; Schmitt A
    Bull Cancer; 2018 Sep; 105(9):790-803. PubMed ID: 30103904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
    Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
    Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
    Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
    J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
    Coriat R; Chaussade S
    Therapie; 2007; 62(2):105-9. PubMed ID: 17582310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
    Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
    Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
    Schneider HB; Becker H
    Eur J Med Res; 2003 May; 8(5):226-8. PubMed ID: 12844478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.